Illumina Inc. ILMN
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · illumina.com
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis globally. Its platforms power applications in genomic research, drug development, oncology testing, reproductive health screening, and population genomics programs. The company serves genomic research centers, academic institutions, pharmaceutical and biotechnology companies, clinical laboratories, and consumer genomics companies worldwide.
Key ratios
FreeCashFlowOnSale TTM 0.21
FreeCashFlowOnSale 2025 0.21
FreeCashFlowOnSale 2024 0.16
FreeCashFlowOnSale 2023 0.06
NetIncomeMargin TTM 0.2
NetIncomeMargin 2025 0.2
NetIncomeMargin 2024 -0.28
NetIncomeMargin 2023 -0.26
ReturnOnAssets TTM 0.08
ReturnOnAssets 2025 0.08
ReturnOnAssets 2024 0.03
ReturnOnAssets 2023 -0
ReturnOnEquity TTM 0.33
ReturnOnEquity 2025 0.33
ReturnOnEquity 2024 -0.3
ReturnOnEquity 2023 -0.19
Recent news
Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors
2026-06-23 · PR Newswire